BioVersys AG

BioVersys AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, dedicated to the research and development of novel antibacterial products. The company's core mission is to combat the global threat of antimicrobial resistance (AMR) by developing innovative medicines for serious, life-threatening infections caused by multi-drug resistant (MDR) bacteria, ultimately aiming to save lives and improve patient outcomes.

Leveraging its proprietary TRIC and Ansamycin chemistry technology platforms, BioVersys focuses on developing new antibacterial drugs that overcome resistance mechanisms, block virulence production, and directly impact bacterial pathogenesis. Its pipeline includes lead candidates such as BV100, currently in a global Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, and Alpibectir, which is in Phase 2 development for tuberculosis. The company also has BV200 targeting methicillin-resistant Staphylococcus aureus (MRSA) infections and BV500 for non-tuberculous mycobacterial infections in collaboration with Shionogi.

BioVersys AG became publicly traded on the SIX Swiss Exchange under the ticker "BIOV" on February 7, 2025. Recent notable developments include the initiation of the global Phase 3 clinical trial for BV100 in April 2026, targeting hospital-acquired and ventilator-associated bacterial pneumonia. Dr. Marc Gitzinger serves as the CEO and co-founder, while Dr. Seng Chin Mah is the Chairman of the Board, which saw all proposals approved at the recent Annual General Meeting in April 2026.